# US 2003/0216402 A1 · Oxo-azabicyclic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216402 A1
- Document ID: US20030216402A1
- Status: Published application
- Kind: A1
- Application number: 10/384,115
- Filed: 2003-03-07
- Published: 2003-11-20
- Earliest claimed: 2002-03-08
- Assignees: Warner-Lambert Company
- Inventors: Bernard Gaudilliere; Henry Jacobelli; Catherine Kostlan; Jack Jie Li; Wen-Song Yue
- Web page: https://patentgrep.com/patent/US20030216402A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 239/91: with aryl or aralkyl radicals attached in position 2 or 3
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A compound selected from those of formula (I): 1 wherein: X1, X2, and X3, represent N or —CR3 in which R3 is as described in the description, G1 represents a group selected from those of formulae (i/a) and (i/b): 2 in which R4, R5, and R6 are as defined in the description, G2 represents a group selected from carbon-carbon triple bond, —CH═C═CH—, C═O, C═S, S(O)n1 in which n1 represents an integer from 0 to 2 inclusive, or a group of formula (i/c): 3 in which Y1 represents O, S, —NH or —Nalkyl, and Y2 represents O, S, —NH or —Nalkyl, n is an integer from 0 to 6 inclusive, and m is an integer from 0 to 7 inclusive, Z1 represents —CR9R10, wherein R9 and R10 are as defined in the description, A represents a ring system, R1 represents a group selected from H, alkyl, alkenyl, alkynyl, optionally substituted and the group of formula (i/d): 4 in which p, Z2, B, q and G3 are as defined in the description and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix mettaloprotease.

## Claims

### Claim at position 1

1- A compound selected from those of formula (I):
119
wherein:
X1, X2, and X3, independently of each other, represent a nitrogen atom or a group —CR3 in which R3 represents a group selected from hydrogen, (C1-C6)alkyl, amino, mono(C1-C6)alkylamino, di(C1-C6)alkylamino, hydroxy, (C1-C6)alkoxy, and halogen, with the proviso that not more than two of the groups X1, X2 and X3 simultaneously represent a nitrogen atom,
G1 represents a group selected from those of formulae (i/a) and (i/b):
120
in which:
the carbon atom with number 2 is attached to the group N—R1 in the ring,
R4 and R5, identical or different, independently of each other, represent a group selected from hydrogen, (C1-C6)alkyl, aryl, aryl(C1-C6)alkyl, cycloalkyl, cycloalkyl(C1-C6)alkyl, heteroaryl, heteroaryl(C1-C6)alkyl, heterocycloalkyl, and heterocycloalkyl(C1-C6)alkyl,
R6 represents a group selected from:
hydrogen, trifluoromethyl, OR7, NR7R8, in which R7 and R8, identical or different independently of each other, represent hydrogen or (C1-C6)alkyl,
(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, aryl, aryl(C1-C6)alkyl, cycloalkyl(C1-C6)alkyl, heteroaryl, heteroaryl(C1-C6)alkyl, heterocycloalkyl, and heterocycloalkyl(C1-C6)alkyl, these groups being optionally substituted by one or more groups, which may be identical or different independently of each other, selected from halogen, amino, mono(C1-C6)alkylamino, di(C1-C6)alkylamino, each alkyl moiety being identical or different independently of each other, cyano, trihalogeno(C1-C6)alkyl, (C1-C6)acyl, —C(═O)OR7, —OR7 and —SR7, in which R7 is as defined hereinbefore,
G2 represents a group selected from carbon-carbon triple bond, —CH═C═CH—, C═O, C═S, S(O)n1 in which n1 represents an integer from 0 to 2 inclusive, and a group of formula (i/c):
121
in which the carbon atom with number 1 is attached to the bicycle of the compound of formula (I), Y1 represents a group selected from oxygen, sulphur, —NH and —N(C1-C6)alkyl, and Y2 represents a group selected from oxygen, sulphur, —NH and —N(C1-C6)alkyl,
n represents an integer from 0 to 6 inclusive,
Z1 represents —CR9R10, wherein R9 and R10, identical or different independently of each other, represent a group selected from hydrogen, (C1-C6)alkyl, trihalogeno(C1-C6)alkyl, halogen, —OR7, —SR7, and —C(═O)OR7, in which R7 is as defined hereinbefore, amino, mono(C1-C6)alkylamino, di(C1-C6)alkylamino in which each alkyl moiety is identical or different independently of each other, and
wherein when n is greater than or equal to 2, the hydrocarbon chain Z1 optionally contains one to two isolated or conjugated multiple bonds,
and/or wherein when n is greater than or equal to 2, one of said —CR9R10 may optionally be replaced with a group selected from oxygen, S(O)n1 in which n1 is as defined hereinbefore, —NH and —N(C1-C6)alkyl,
A represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being 5- or 6-menbered monocycle or bicycle composed of two 5- or 6-membered monocycle,
R1 represents a group selected from:
hydrogen,
(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, these groups may be optionally substituted with one or more groups, which may be identical or different independently of each other, selected from amino, cyano, trihalogeno(C1-C6)alkyl, cycloalkyl, —C(═O)NR7R8, —C(═O)OR8, OR8, SR8, in which R7 and R8, which may be identical or different independently of each other, represent hydrogen or (C1-C6)alkyl,
and the group of formula (i/d):
122
in which p is an integer from 0 to 8 inclusive,
Z2 represents —CR11R12 wherein R11 and R12, identical or different independently of each other, represent a group selected from hydrogen, (C1-C6)alkyl, phenyl, trihalogeno(C1-C6)alkyl, halogen, amino, OR7, SR7 and —C(═O)OR7 in which R7 represents hydrogen or (C1-C6)alkyl, and
wherein when p is greater than or equal to 2, the hydrocarbon chain Z2 optionally contains one or two isolated or conjugated multiple bonds,
and/or wherein n is greater than or equal to 2, one of said —CR11R12 may optionally be replaced with a group selected from oxygen, S(O)n1 in which n1 is as defined hereinbefore, —NH, —N(C1-C6)alkyl, and carbonyl,
B represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being 5- or 6-menbered monocycle or bicycle composed of two 5- or 6-membered monocycle,
q is an integer from 0 to 7 inclusive,
the group(s) G3, which may be identical or different independently of each other, is (are) selected from (C1-C6)alkyl, halogen, CN, NO2, CF3, OCF3, —(CH2)kNR13R14, —N(R13)C(═O)R14, —N(R13)C(═O)OR14, —N(R13)SO2R14, —N(SO2R13)2, —OR13, —S(O)k1R13, —SO2—N(R13)—(CH2)k2—NR14R15, —(CH2)kSO2NR13R14, —X4(CH2)kC(═O)OR13, —(CH2)kC(═O)OR13, —C(═O)O—(CH2)k2—NR13R14, —C(═O)O—(CH2)k2—C(═O)OR16, —X4(CH2)kC(═O)NR13R14, —(CH2)kC(═O)NR13R14, —R17—C(═O)OR13, —X5—R18, and —C(═O)—R19—NR13R14 in which:
X4 represents a group selected from oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by a hydrogen atom or a (C1-C6)alkyl group,
k is an integer from 0 to 3 inclusive,
k1 is an integer from 0 to 2 inclusive,
k2 is an integer from 1 to 4 inclusive,
R13, R14 and R15, which may be identical or different independently of each other, are selected from hydrogen and (C1-C6)alkyl,
R16 represents a group selected from (C1-C6)alkyl, —R19—NR13R14, —R19—NR13—C(═O)—R19—NR14R15, and —C(═O)O—R19—NR13R14 in which R19 represents a linear or branched (C1-C6)alkylene group, and R13, R14 and R15 are as defined hereinbefore,
R17 represents a (C3-C6)cycloalkyl group,
X5 represents a group selected from single bond, —CH2—, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C1-C6)alkyl group,
R18 represents a group selected from:
5- or 6-menbered monocycle aryl, heteroaryl, which is optionally substituted by one or more groups, which may be identical or different, selected from (C1-C6)alkyl, halogen, hydroxy, cyano, tetrazolyl, amino, and —C(═O)OR7 wherein R7 represents hydrogen or (C1-C6)alkyl,
and 5- or 6-menbered monocycle cycloalkyl, heterocycloalkyl, which is optionally substituted by one or more groups, which may be identical or different, selected from (C1-C6)alkyl, halogen, hydroxy, oxo, cyano, tetrazolyl, amino, and —C(═O)OR7 wherein R7 represents hydrogen or (C1-C6)alkyl,
m is an integer from 0 to 7 inclusive,
the group(s) R2, which may be identical or different independently of each other, is (are) selected from (C1-C6)alkyl, halogen, —CN, NO2, SCF3, —CF3, —OCF3, —NR7R8, —OR8, —SR8, —SOR8, —SO2R8, —(CH2)kSO2NR7R8, —X7(CH2)kC(═O)OR8, —(CH2)kC(═O)OR8, —X7(CH2)kC(═O)NR7R8, —(CH2)kC(═O)NR7R8, and —X8—R20 in which:
X7 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen atoms, and nitrogen substituted by hydrogen or (C1-C6)alkyl,
k is an integer from 0 to 3 inclusive,
R7 and R8, which may be identical or different independently of each other, are selected from hydrogen and (C1-C6)alkyl,
X8 represents a group selected from single bond, —CH2—, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C1-C6)alkyl group,
R20 represents 5- or 6-menbered monocycle aryl, heteroaryl, cycloalkyl, or heterocycloalkyl which is optionally substituted by one or more groups, which may be identical or different, selected from (C1-C6)alkyl, halogen, hydroxy and amino, and when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof,
it being understood that when no specification are described:
an aryl group denotes an aromatic monocyclic or bicyclic system containing from 5 to 10 carbon atoms, and in the case of a bicyclic system, one of the ring of which is aromatic in character, and the other ring of which may be aromatic or partially hydrogenated,
a heteroaryl group denotes an aryl group as described above in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur and nitrogen,
a cycloalkyl group denotes a monocyclic or bicyclic system containing from 3 to 10 carbon atoms, this system being saturated or partially unsaturated but without aromatic character,
and a heterocycloalkyl group denotes a cycloalkyl group as defined hereinbefore in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen.

### Claim at position 2 (depends on 1)

2- A compound according to claim 1 wherein:
G2 represents a group selected from C═O, C═S, S(O)n1 in which n1 represents an integer from 0 to 2 inclusive, or a group of formula (i/c):
123
in which the carbon atom with number 1 is attached to the bicycle of the compound of formula (I), Y1 represents a group selected from oxygen, sulphur, —NH and —N(C1-C6)alkyl, and Y2 represents a group selected from oxygen, sulphur, —NH and —N(C1-C6)alkyl,
X1, X2, X3, G1, n, Z1, A, R1, m and R2 are as defined in formula (I), optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

### Claim at position 3 (depends on 1)

3- A compound according to claim 1 wherein:
G2 represents a carbon-carbon triple bond,
n represents an integer from 1 to 6 inclusive,
X1, X2, X3, G1, Z1, A, R1, m and R2 are as defined in formula (I), optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

### Claim at position 4 (depends on 1)

4- A compound according to claim 1, which is selected from:
3-(4-methoxy-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
3-(4-methoxy-benzyl)-2-methyl-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide, hydrochloride
3-(4-methoxy-benzyl)-1-methyl-4-oxo-1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
3-(4-methoxy-benzyl)-1,2,2-trimethyl-4-oxo-1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
4-[6-(4-methoxy-benzylcarbamoyl)-4-oxo-1,4-dihydro-2H-quinazolin-3-ylmethyl]-benzoic acid
4-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-4-oxo-1,4-dihydro-2H-quinazolin-3-ylmethyl]-benzoic acid methyl ester
4-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-4-oxo-1,4-dihydro-2H-quinazolin-3-ylmethyl]-benzoic acid,
3-(4-fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 3-methoxy-benzylamide
3-(4-methanesulfonyl-benzyl-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
4-Oxo-3-[4-(pyrrolidine-1-sulfonyl)-benzyl]-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
4-[6-(3-methoxy-benzylcarbamoyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid,
3-(4-fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide,
3-(3-fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide,
3-(3-fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide
3-(3,4-Difluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide and
3-(3,4-Difluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide.

### Claim at position 5 (depends on 1)

5- A compound according to claim 1, which is selected from:
3-(4-fluorobenzyl)-6-(3-phenyl-prop-1-ynyl)-3 H-quinazolin-4-one,
methyl 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoate,
4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid,
3-(4-fluorobenzyl)-6-(3-phenyl-prop-1-ynyl)-3H-pyrido[3,4-d]pyrimidin-4-one,
methyl 4-[6-(3-phenyl-prop-1-ynyl)-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl]-benzoate,
4-[6-(3-phenyl-prop-1-ynyl)-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl]-benzoic acid,
4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazoline-3-ylmethyl]-benzoic acid,
4-{6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-4-oxo-4H-quinazoline-3-ylmethyl}-benzoic acid,
4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazoline-3-ylmethyl]-benzamide
3-[(3,5-difluoro-4-hydroxy)-benzyl]-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one
4-[6-(3-Imidazol-1-yl-prop-1-ynyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid
4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzenesulfonamide
4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzonitrile
3-(3-Chloro-benzyl)-6-(4-phenyl-but-1-ynyl)-3H-quinazolin-4-one
3-(3-Chloro-benzyl)-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one
4-[4-Oxo-6-(3-pyrazol-1-yl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid
6-(3-Phenyl-prop-1-ynyl)-3-[4-(1H-tetrazol-5-yl)-benzyl]-3H-quinazolin-4-one
3-(3,4-Difluoro-benzyl)-6-[3-(pyridin-4-yloxy)-prop-1-ynyl]-3H-quinazolin-4-one
3-(3,4-Difluoro-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
N-{4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-phenyl}-acetamide
3-(3,4-Difluoro-benzyl)-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one
3-(4-Acetyl-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
6-(3-Phenyl-prop-1-ynyl)-3-pyridin-4-ylmethyl-3H-quinazolin-4-one and
6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-3-pyridin-4-ylmethyl-3H-quinazolin-4-one.

### Claim at position 6 (depends on 1)

6- A compound according to claim 1, which is selected from:
Methyl 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]benzoate
4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid
4-[6-(3-Methoxy-benzylcarbamoyl)-4-oxo-4H-quinazolin-3-ylmethyl]benzoic acid
4-{6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-4-oxo-4H-quinazoline-3-ylmethyl}-benzoic acid
3-(3-Fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6 carboxylic acid 3-methoxy-benzylamide
3-(3-Fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6 carboxylic acid 4-methoxy-benzylamide
4-[6-(3-Imidazol-1-yl-prop-1-ynyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid
4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzenesulfonamide
4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzonitrile
6-(3-Phenyl-prop-1-ynyl)-3-[4-(1H-tetrazol-5-yl)-benzyl]-3H-quinazolin-4-one
3-(3,4-Difluoro-benzyl)-6-[3-(pyridin-4-yloxy)-prop-1-ynyl]-3H-quinazolin-4-one
3-(3,4-Difluoro-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
N-{4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-phenyl}-acetamide
3-(4-Acetyl-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
6-(3-Phenyl-prop-1-ynyl)-3-pyridin-4-ylmethyl-3H-quinazolin-4-one and
6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-3-pyridin-4-ylmethyl-3H-quinazolin-4-one.

### Claim at position 7 (depends on 1)

7- A pharmaceutical composition, comprising as active ingredient an effective amount of a compound as claimed in claim 1, in combination with a pharmaceutically-acceptable excipient or carrier.

### Claim at position 8 (depends on 1)

8- A method for treating a living body afflicted with a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration, and cancers, comprising the step of administering to the living body an amount of a compound of claim 1 which is effective for alleviation of said disease.

### Claim at position 9 (depends on 8)

9- The method according to claim 8,wherein the disease is arthritis.

### Claim at position 10 (depends on 8)

10- The method according to claim 8,wherein the disease is osteoarthritis.

### Claim at position 11 (depends on 8)

11- The method according to claim 8,wherein the disease is rheumatoid arthritis.
